Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pindolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 12/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | HTR1B | P28222 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pindolol SCHEMBL1157882 | 1.00 | HTR1A (1.00) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL5220 | 1.00 | HTR1A (1.00) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL29908300 | 1.00 | HTR1A (1.00) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL5219 | 1.00 | HTR1A (1.00) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL29379249 | 1.00 | HTR1A (1.00) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL561162 | 0.99 | HTR1A (0.97) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL2991558 | 0.99 | HTR1A (0.97) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Pindolol SCHEMBL10494992 | 0.95 | HTR1A (0.91) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Propranolol SCHEMBL540824 | 0.93 | HTR1A (0.87) | HTR1AADRB2ADRB1CYP1A2ADRB3 | |
| Propranolol SCHEMBL20508988 | 0.92 | HTR1A (0.85) | HTR1AADRB2ADRB1CYP1A2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170209477-A1 | COMPOSITIONS FOR AMELIORATING SYSTEMIC INFLAMMATION AND METHODS FOR MAKING AND USING THEM | VICUS THERAPEUTICS LLC (US) | 2017-07-27 | — | — | US | claimed |
| US-20140170112-A1 | COMPOSITIONS FOR AMELIORATING SYSTEMIC INFLAMMATION AND METHODS FOR MAKING AND USING THEM | VICUS THERAPEUTICS, LLC (US) | 2014-06-19 | — | — | US | claimed |
| WO-2012125413-A2 | COMPOSITIONS FOR AMELIORATING SYSTEMIC INFLAMMATION AND METHODS FOR MAKING AND USING THEM | VICUS THERAPEUTICS, LLC (US) | 2012-09-20 | — | — | WO | claimed |
| CN-101323580-A | Synthetic methods of chiral aryloxy propanol amine compounds and salts thereof | UNIV HEBEI SCIENCE & TECH (CN) | 2008-12-17 | — | — | CN | claimed |
| US-20260108490-A1 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER | NOVARTIS PHARMA AG (CH) | 2026-04-23 | — | — | US | disclosed |
| US-12533340-B2 | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker | NOVARTIS AG (CH) | 2026-01-27 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| US-11944602-B2 | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker | NOVARTIS AG (CH) | 2024-04-02 | — | — | US | disclosed |
| CN-111712241-B | Sigma-1 receptor agonist systolic blood pressure therapy | 阿纳韦克斯生命科学公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230355577-A1 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER | NOVARTIS PHARMA AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | RDE PHARMA | 2022-07-21 | — | — | US | disclosed |
| US-6500827-B2 | Drug combinations | PHARMACIA & UPJOHN COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-20020040041-A1 | New drug combinations | TAYLOR DUNCAN PAUL (US) | 2002-04-04 | — | — | US | disclosed |
| US-20020016325-A1 | New drug combinations | TAYLOR DUNCAN PAUL (US) | 2002-02-07 | — | — | US | disclosed |
| EP-1075264-A1 | NEW DRUG COMBINATIONS OF A N.A.R.I., PREFERABLY REBOXETINE, AND PINDOLOL | PHARMACIA & UPJOHN COMPANY (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999058130-A1 | NEW DRUG COMBINATIONS OF A N.A.R.I., PREFERABLY REBOXETINE, AND PINDOLOL | PHARMACIA & UPJOHN COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |
| EP-0000174-B1 | DERIVATIVES OF AMINOBENZOIC ACIDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | Ludwig Merckle GmbH & Co. chem.-pharm. Fabrik (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4294851-A | ANTILIPEMIC AGENTS, ANTIARRHYTHMIA AGENTS | METZ GUNTER | 1981-10-13 | — | — | US | disclosed |
| EP-0000174-A1 | Derivatives of aminobenzoic acids, process for their preparation and pharmaceutical compositions containing them. | Ludwig Merckle GmbH & Co. chem.-pharm. Fabrik (DE) | 1979-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944602-B2 | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker | ADRA2B, ADRB2, TGFB2 | ADRB2 2/4885ADRB1 5/4885HTR1A 2703/4885 |
| US-20260108490-A1 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER | PMP22, PSMB2, SMN1; SMN2 | ADRB2 43/4885ADRB1 214/4885HTR1A 3283/4885 |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | PAH, BPGM, TPMT | ADRB2 1682/4885ADRB1 1330/4885HTR1A 2576/4885 |
| US-12533340-B2 | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker | SCN2B, SCN1B, ADRB2 | ADRB2 3/4885ADRB1 18/4885HTR1A 983/4885 |
| US-20230355577-A1 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER | ADRA2B, ADRB2, TGFB2 | ADRB2 2/4885ADRB1 5/4885HTR1A 2703/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | ADRB2 2941/4885ADRB1 2832/4885HTR1A 4024/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | ADRB2 1967/4885ADRB1 1777/4885HTR1A 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.